Cover Image
Market Research Report

Biosimilars Market Size By Product, By Application, By Manufacturer, By Technology Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 - 2025

Published by Global Market Insights Inc. Product code 862161
Published Content info 600 Pages
Delivery time: 2-3 business days
Price
Back to Top
Biosimilars Market Size By Product, By Application, By Manufacturer, By Technology Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 - 2025
Published: May 14, 2019 Content info: 600 Pages
Description

Title:
Biosimilars Market Size By Product (Recombinant Non-Glycosylated Proteins {Human Growth Hormone, Granulocyte Colony-Stimulating Factor, Insulin, Interferon}, Recombinant Glycosylated Proteins {Erythropoietin, Monoclonal Antibodies, Follitropin, Low Molecular Weight Heparin}), By Application (Haematology {Neutropenia, Anaemia}, Oncology {Lung Cancer, Brain Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Leukaemia or Blood Cancer}, Autoimmune Disease {Arthritis, Inflammatory Bowel Disease, Psoriasis}, Growth Hormone Deficiency, Diabetes), By Manufacturer (Contract Research and Manufacturing Services, In-house), By Technology (Recombinant DNA Technology, Monoclonal Antibodies Technology) Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Russia, Turkey, Austria, Belgium, Bulgaria, Czech Republic, Denmark, Finland, Greece, Hungary, Ireland, Netherlands, Norway, Romania, Slovakia, Slovenia, Sweden, Switzerland, China, Japan, India, South Korea, Australia, New Zealand, Singapore, Malaysia, Rest of The World), Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 - 2025.

Biosimilars Market will exceed USD 69 billion by 2025; as per a new research report.

Biosimilars market is estimate to growth at a significant rate over the forecast period. Biosimilars are estimated to play a substantial role in enhancing public health issue by addressing the customer needs. It is estimated that biosimilars would result in total potential savings of around over USD 100 billion by the year 2020. Increase in demand for biosimilar drugs in order to reduce the healthcare cost will be one of the major market boosting factors.

Growing prevalence of chronic disorders across the globe, especially in developing regions of Asia Pacific and Latin America owing to rise in sedentary lifestyle among the population and growing habit of fast food consumption will result in growing number of people suffering from such diseases. Hence, increased prevalence rate in developed as well as in certain areas in developing nations will augment the demand and adoption rate of biosimilar drugs, fueling the business growth.

However, high biosimilar development cost will be one of the major reasons hampering the adoption rates in under-developed and few developing countries. It takes around 7 to 8 years and costs around USD 100 million to USD 250 million to develop a biosimilar. Hence, high cost related to biosimilar drugs development will continue to hinder market growth over the forecast timeframe.

Recombinant non-glycosylated proteins market held the majority market share in the year 2018 and is estimated to grow at around 26.1% over the estimation period. Recombinant non-glycosylated proteins include human growth hormone, granulocyte colony-stimulating factor (Filgrastim), insulin and interferon. Recent technological developments in high-throughput analytical techniques and cell technology will help in effective production of products resulting in enhanced sales. Also, recent launch of insulin glargine in major countries and growing demand of filgrastim will further augment the biosimilars market growth.

Application of biosimilars is highest in hematology segment resulting in major market share. The hematology segment accounted for around USD 4,552.1 million revenue in the year 2018. As per the American Society of Hematology, around 3 million American suffer from anemia. Increase in number of people suffering from blood disorders such as neutropenia, anemia etc. will boost the sales of biosimilars.

In-house manufacturing of biosimilars held around 75% market share in the year 2018 and is forecasted to grow at around 26.5% over the projection period. Several benefits offered by in-house manufacturing facilities has helped the companies to monitor and assess the production and reduce other costs of delivery and shipping. Also, several other advantages of in-house manufacturing such as flexibility and efficiency of the work will increase the operational and financial capabilities of the company. Hence, currently in-house manufacturing of biosimilar products will have major market share.

Development of biosimilars by recombinant DNA technology (rDNA technology) held over 80% market share and was valued at USD 8,123.6 million in the year 2018. Biosimilar products such as human growth hormones, insulin, erythropoietin etc. are manufactured using recombinant DNA technology. The use of rDNA technology improves the capability of the biosimilars to treat ailment immediately and efficiently. Hence, manufacturers use the recombinant DNA technology in order to manufacture biosimilar products.

U.S. dominated the North America biosimilars market and is estimated to witness significant growth at 38.1% over the forecast period. Presence of new technology, state-of-art facilities for biosimilar production, established and big pharma players market presence has resulted in the U.S. capturing majority market share of the North America biosimilars market. Also, recent biosimilar approvals by FDA in the year 2015 will result in rapid biosimilar adoption, augmenting the market growth. During the forecast years, it will witness significant growth owing to relatively low addressable needs.

Amgen, Biocon, Biogen, Boehringer Ingelheim, Celltrion, Coherus BioSciences are some of the major industry participants operating in the global biosimilars market. Various firms are entering in less addressed and high potential geographies in order to expand their industry presence. Also, introduction and development of several biosimilar drug in developing countries by major local companies will result in augmenting the market growth.

Table of Contents
Product Code: 3328

Table of Contents

Chapter 1. Methodology

  • 1.1. Methodology
  • 1.2. Market definition
  • 1.3. Forecast parameters
  • 1.4. Data sources
    • 1.4.1. Secondary
      • 1.4.1.1. Paid sources
      • 1.4.1.2. Unpaid sources
    • 1.4.2. Primary

Chapter 2. Executive Summary

  • 2.1. Biosimilars industry 360 degree synopsis, 2014 - 2025 (USD Million)
    • 2.1.1. Business trends
    • 2.1.2. Product trends
    • 2.1.3. Application trends
    • 2.1.4. Manufacturer trends
    • 2.1.5. Technology trends
    • 2.1.6. Regional trends

Chapter 3. Biosimilars Industry Insights

  • 3.1. Industry segmentation
  • 3.2. Industry landscape, 2014 - 2025 (USD Million)
  • 3.3. Industry impact factors
    • 3.3.1. Growth drivers
      • 3.3.1.1. Emphasis on reducing healthcare cost in developed economies of Europe
      • 3.3.1.2. Cost effectiveness of biosimilars in U.S.
      • 3.3.1.3. Increase in R&D activities in the developing countries of Asia Pacific
      • 3.3.1.4. Patent expiration of biologics
      • 3.3.1.5. Rise in prevalence of chronic diseases across the globe
      • 3.3.1.6. Recent biosimilar product approvals in major countries
      • 3.3.1.7. Strong product pipeline
    • 3.3.2. Industry pitfalls & challenges
      • 3.3.2.1. High development cost of biosimilar drugs
      • 3.3.2.2. Presence of biologics and bio-betters
      • 3.3.2.3. Regulatory uncertainty
      • 3.3.2.4. Interchangeability
  • 3.4. Growth potential analysis
    • 3.4.1. By product
    • 3.4.2. By application
    • 3.4.3. By manufacturer
    • 3.4.4. By technology
  • 3.5. Regulatory landscape
    • 3.5.1. U.S.
    • 3.5.2. Canada
    • 3.5.3. Europe
    • 3.5.4. India
    • 3.5.5. Japan
    • 3.5.6. South Korea
    • 3.5.7. Australia
    • 3.5.8. Singapore
  • 3.6. Reimbursement landscape
    • 3.6.1. Europe
    • 3.6.2. Canada
    • 3.6.3. Australia
    • 3.6.4. New Zealand
  • 3.7. Market analysis
    • 3.7.1. Strength
    • 3.7.2. Weakness
    • 3.7.3. Opportunity
    • 3.7.4. Threat
  • 3.8. U.S. biosimilars insurance coverage, 2017
  • 3.9. Biosimilar litigation landscape
  • 3.10. Biosimilar product pipeline analysis
    • 3.10.1. Amgen
    • 3.10.2. Biocon
    • 3.10.3. Boehringer Ingelheim
    • 3.10.4. Celltrion
    • 3.10.5. Coherus BioSciences
    • 3.10.6. Dr. Reddy's Laboratories
    • 3.10.7. Lupin
    • 3.10.8. Merck
    • 3.10.9. Novartis (Sandoz)
    • 3.10.10. Pfizer
    • 3.10.11. Samsung Bioepis
    • 3.10.12. Teva Pharmaceutical
    • 3.10.13. Zydus Cadila
  • 3.11. Biosimilars approval scenario, 2018
    • 3.11.1. U.S.
    • 3.11.2. Canada
    • 3.11.3. Europe
    • 3.11.4. Japan
    • 3.11.5. India
    • 3.11.6. South Korea
    • 3.11.7. Australia
    • 3.11.8. New Zealand
    • 3.11.9. Singapore
    • 3.11.10. Malaysia
  • 3.12. Patent expiry scenario
  • 3.13. Biosimilars industry evolution
    • 3.13.1. U.S.
    • 3.13.2. Europe
  • 3.14. Biosimilars factor analysis
    • 3.14.1. Access
    • 3.14.2. Regulations
    • 3.14.3. Payer assessment and access
    • 3.14.4. Physician acceptance
    • 3.14.5. Patient acceptance
    • 3.14.6. Number of biosimilar approvals
  • 3.15. Biosimilars landscape - country analysis
    • 3.15.1. U.S.
    • 3.15.2. Europe
    • 3.15.3. China
    • 3.15.4. Japan
    • 3.15.5. India
    • 3.15.6. South Korea
  • 3.16. Key market success factors
  • 3.17. International policies on use of biosimilar drugs
    • 3.17.1. Interchangeability, Switching and Substitution
    • 3.17.2. Supply Side Policies
    • 3.17.3. Prescribing Incentives
  • 3.18. Porter's analysis
  • 3.19. Competitive landscape, 2017
    • 3.19.1. Strategy dashboard
  • 3.20. PESTEL analysis

Chapter 4. Biosimilars Market, By Product

  • 4.1. Global biosimilars market share by product, 2018 & 2025
  • 4.2. Recombinant Non-Glycosylated Proteins
    • 4.2.1. Market size, by region, 2014 - 2025 (USD Million)
    • 4.2.2. Human Growth Hormone
      • 4.2.2.1. Market size, by region, 2014 - 2025 (USD Million)
    • 4.2.3. Granulocyte Colony-Stimulating Factor (Filgrastim)
      • 4.2.3.1. Market size, by region, 2014 - 2025 (USD Million)
    • 4.2.4. Insulin
      • 4.2.4.1. Market size, by region, 2014 - 2025 (USD Million)
    • 4.2.5. Interferon
      • 4.2.5.1. Market size, by region, 2014 - 2025 (USD Million)
      • 4.2.5.2. Alfa
        • 4.2.5.2.1. Market size, by region, 2014 - 2025 (USD Million)
      • 4.2.5.3. Beta
        • 4.2.5.3.1. Market size, by region, 2014 - 2025 (USD Million)
  • 4.3. Recombinant Glycosylated Proteins
    • 4.3.1. Market size, by region, 2014 - 2025 (USD Million)
    • 4.3.2. Erythropoietin
      • 4.3.2.1. Market size, by region, 2014 - 2025 (USD Million)
      • 4.3.2.2. Alfa
        • 4.3.2.2.1. Market size, by region, 2014 - 2025 (USD Million)
      • 4.3.2.3. Zeta
        • 4.3.2.3.1. Market size, by region, 2014 - 2025 (USD Million)
    • 4.3.3. Monoclonal Antibodies
      • 4.3.3.1. Market size, by region, 2014 - 2025 (USD Million)
      • 4.3.3.2. Infliximab
        • 4.3.3.2.1. Market size, by region, 2014 - 2025 (USD Million)
      • 4.3.3.3. Rituximab
        • 4.3.3.3.1. Market size, by region, 2014 - 2025 (USD Million)
      • 4.3.3.4. Adalimumab
        • 4.3.3.4.1. Market size, by region, 2014 - 2025 (USD Million)
      • 4.3.3.5. Trastuzumab
        • 4.3.3.5.1. Market size, by region, 2014 - 2025 (USD Million)
      • 4.3.3.6. Bevacizumab
        • 4.3.3.6.1. Market size, by region, 2014 - 2025 (USD Million)
      • 4.3.3.7. Etanercept
        • 4.3.3.7.1. Market size, by region, 2014 - 2025 (USD Million)
    • 4.3.4. Follitropin
      • 4.3.4.1. Market size, by region, 2014 - 2025 (USD Million)
      • 4.3.4.2. Alfa
        • 4.3.4.2.1. Market size, by region, 2014 - 2025 (USD Million)
      • 4.3.4.3. Beta
        • 4.3.4.3.1. Market size, by region, 2014 - 2025 (USD Million)
    • 4.3.5. Low Molecular Weight Heparin (LMWHs)
      • 4.3.5.1. Market size, by region, 2014 - 2025 (USD Million)

Chapter 5. Biosimilars Market, By Application

  • 5.1. Global biosimilars market share by application, 2018 & 2025
  • 5.2. Hematology
    • 5.2.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.2.2. Neutropenia
      • 5.2.2.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.2.3. Anemia
      • 5.2.3.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.2.4. Others
      • 5.2.4.1. Market size, by region, 2014 - 2025 (USD Million)
  • 5.3. Oncology
    • 5.3.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.3.2. Lung Cancer
      • 5.3.2.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.3.3. Brain Cancer
      • 5.3.3.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.3.4. Breast Cancer
      • 5.3.4.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.3.5. Cervical Cancer
      • 5.3.5.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.3.6. Colorectal Cancer
      • 5.3.6.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.3.7. Leukemia
      • 5.3.7.1. Market size, by region, 2014 - 2025 (USD Million)
      • 5.3.7.2. Non-Hodgkin Lymphoma (NHL)
        • 5.3.7.2.1. Market size, by region, 2014 - 2025 (USD Million)
      • 5.3.7.3. Chronic Lymphocytic Leukemia (CLL)
        • 5.3.7.3.1. Market size, by region, 2014 - 2025 (USD Million)
      • 5.3.7.4. Others
        • 5.3.7.4.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.3.8. Others
      • 5.3.8.1. Market size, by region, 2014 - 2025 (USD Million)
  • 5.4. Autoimmune Disease
    • 5.4.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.4.2. Arthritis
      • 5.4.2.1. Market size, by region, 2014 - 2025 (USD Million)
      • 5.4.2.2. Rheumatoid Arthritis
        • 5.4.2.2.1. Market size, by region, 2014 - 2025 (USD Million)
      • 5.4.2.3. Psoriatic Arthritis
        • 5.4.2.3.1. Market size, by region, 2014 - 2025 (USD Million)
      • 5.4.2.4. Juvenile Arthritis
        • 5.4.2.4.1. Market size, by region, 2014 - 2025 (USD Million)
      • 5.4.2.5. Ankylosing Spondylitis
        • 5.4.2.5.1. Market size, by region, 2014 - 2025 (USD Million)
      • 5.4.2.6. Others
        • 5.4.2.6.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.4.3. Inflammatory Bowel Disease (IBD)
      • 5.4.3.1. Market size, by region, 2014 - 2025 (USD Million)
      • 5.4.3.2. Ulcerative Colitis
        • 5.4.3.2.1. Market size, by region, 2014 - 2025 (USD Million)
      • 5.4.3.3. Crohn's Disease
        • 5.4.3.3.1. Market size, by region, 2014 - 2025 (USD Million)
      • 5.4.3.4. Others
        • 5.4.3.4.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.4.4. Psoriasis
      • 5.4.4.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.4.5. Others
      • 5.4.5.1. Market size, by region, 2014 - 2025 (USD Million)
  • 5.5. Growth Hormone Deficiency
    • 5.5.1. Market size, by region, 2014 - 2025 (USD Million)
  • 5.6. Diabetes
    • 5.6.1. Market size, by region, 2014 - 2025 (USD Million)
  • 5.7. Others
    • 5.7.1. Market size, by region, 2014 - 2025 (USD Million)

Chapter 6. Biosimilars Market, By Manufacturer

  • 6.1. Global biosimilars market share by manufacturer, 2018 & 2025
  • 6.2. Contract Research and Manufacturing Services
    • 6.2.1. Market size, by region, 2014 - 2025 (USD Million)
  • 6.3. In-house
    • 6.3.1. Market size, by region, 2014 - 2025 (USD Million)

Chapter 7. Biosimilars Market, By Technology

  • 7.1. Global biosimilars market share by technology, 2018 & 2025
  • 7.2. Recombinant DNA Technology (rDNA technology)
    • 7.2.1. Market size, by region, 2014 - 2025 (USD Million)
  • 7.3. Monoclonal Antibodies (MAb) Technology
    • 7.3.1. Market size, by region, 2014 - 2025 (USD Million)

Chapter 8. Biosimilars Market, By Region

  • 8.1. Global biosimilars market share by region, 2018 & 2025
  • 8.2. North America
    • 8.2.1. Market size, by country, 2014 - 2025 (USD Million)
    • 8.2.2. Market size, by product, 2014 - 2025 (USD Million)
      • 8.2.2.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
      • 8.2.2.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.2.2.2.1. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
    • 8.2.3. Market size, by application, 2014 - 2025 (USD Million)
      • 8.2.3.1. Market size, by hematology, 2014 - 2025 (USD Million)
      • 8.2.3.2. Market size, by oncology, 2014 - 2025 (USD Million)
        • 8.2.3.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
      • 8.2.3.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
        • 8.2.3.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
        • 8.2.3.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
    • 8.2.4. Market size, by manufacturer, 2014 - 2025 (USD Million)
    • 8.2.5. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.2.6. U.S.
      • 8.2.6.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.2.6.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.2.6.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.2.6.1.2.1. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
      • 8.2.6.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.2.6.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.2.6.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
        • 8.2.6.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.2.6.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
        • 8.2.6.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
        • 8.2.6.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.2.6.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.2.6.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.2.7. Canada
      • 8.2.7.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.2.7.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.2.7.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.2.7.1.2.1. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
      • 8.2.7.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.2.7.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.2.7.2.2. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
        • 8.2.7.2.2.1. Market size, by arthritis, 2014 - 2025 (USD Million)
        • 8.2.7.2.2.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.2.7.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.2.7.4. Market size, by technology, 2014 - 2025 (USD Million)
  • 8.3. Europe
    • 8.3.1. Market size, by country, 2014 - 2025 (USD Million)
    • 8.3.2. Market size, by product, 2014 - 2025 (USD Million)
      • 8.3.2.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.3.2.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
      • 8.3.2.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.3.2.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
        • 8.3.2.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
        • 8.3.2.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
    • 8.3.3. Market size, by application, 2014 - 2025 (USD Million)
      • 8.3.3.1. Market size, by hematology, 2014 - 2025 (USD Million)
      • 8.3.3.2. Market size, by oncology, 2014 - 2025 (USD Million)
        • 8.3.3.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
      • 8.3.3.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
        • 8.3.3.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
        • 8.3.3.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
    • 8.3.4. Market size, by manufacturer, 2014 - 2025 (USD Million)
    • 8.3.5. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.6. Germany
      • 8.3.6.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.6.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.6.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.6.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.6.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.6.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.6.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.6.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.6.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.6.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.6.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.6.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.6.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.6.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.6.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.6.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.7. UK
      • 8.3.7.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.7.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.7.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.7.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.7.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.7.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.7.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.7.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.7.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.7.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.7.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.7.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.7.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.7.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.7.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.7.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.8. France
      • 8.3.8.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.8.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.8.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.8.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.8.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.8.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.8.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.8.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.8.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.8.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.8.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.8.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.8.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.8.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.8.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.8.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.9. Spain
      • 8.3.9.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.9.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.9.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.9.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.9.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.9.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.9.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.9.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.9.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.9.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.9.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.9.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.9.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.9.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.9.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.9.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.10. Italy
      • 8.3.10.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.10.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.10.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.10.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.10.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.10.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.10.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.10.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.10.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.10.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.10.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.10.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.10.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.10.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.10.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.10.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.11. Russia
      • 8.3.11.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.11.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.11.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.11.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.11.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.11.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.11.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.11.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.11.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.11.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.11.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.11.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.11.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.11.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.11.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.11.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.12. Turkey
      • 8.3.12.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.12.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.12.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.12.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.12.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.12.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.12.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.12.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.12.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.12.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.12.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.12.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.12.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.12.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.12.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.12.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.13. Austria
      • 8.3.13.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.13.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.13.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.13.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.13.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.13.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.13.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.13.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.13.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.13.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.13.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.13.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.13.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.13.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.13.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.13.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.14. Belgium
      • 8.3.14.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.14.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.14.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.14.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.14.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.14.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.14.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.14.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.14.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.14.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.14.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.14.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.14.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.14.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.14.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.14.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.15. Bulgaria
      • 8.3.15.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.15.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.15.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.15.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.15.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.15.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.15.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.15.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.15.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.15.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.15.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.15.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.15.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.15.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.15.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.15.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.16. Czech Republic
      • 8.3.16.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.16.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.16.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.16.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.16.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.16.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.16.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.16.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.16.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.16.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.16.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.16.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.16.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.16.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.16.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.16.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.17. Denmark
      • 8.3.17.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.17.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.17.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.17.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.17.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.17.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.17.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.17.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.17.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.17.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.17.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.17.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.17.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.17.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.17.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.17.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.18. Finland
      • 8.3.18.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.18.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.18.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.18.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.18.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.18.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.18.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.18.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.18.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.18.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.18.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.18.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.18.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.18.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.18.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.18.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.19. Greece
      • 8.3.19.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.19.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.19.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.19.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.19.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.19.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.19.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.19.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.19.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.19.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.19.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.19.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.19.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.19.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.19.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.19.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.20. Hungary
      • 8.3.20.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.20.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.20.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.20.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.20.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.20.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.20.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.20.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.20.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.20.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.20.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.20.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.20.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.20.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.20.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.20.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.21. Ireland
      • 8.3.21.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.21.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.21.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.21.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.21.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.21.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.21.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.21.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.21.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.21.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.21.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.21.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.21.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.21.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.21.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.21.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.22. Netherlands
      • 8.3.22.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.22.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.22.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.22.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.22.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.22.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.22.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.22.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.22.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.22.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.22.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.22.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.22.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.22.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.22.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.22.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.23. Norway
      • 8.3.23.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.23.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.23.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.23.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.23.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.23.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.23.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.23.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.23.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.23.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.23.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.23.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.23.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.23.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.23.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.23.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.24. Romania
      • 8.3.24.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.24.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.24.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.24.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.24.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.24.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.24.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.24.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.24.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.24.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.24.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.24.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.24.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.24.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.24.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.24.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.25. Slovakia
      • 8.3.25.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.25.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.25.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.25.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.25.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.25.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.25.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.25.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.25.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.25.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.25.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.25.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.25.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.25.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.25.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.25.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.26. Slovenia
      • 8.3.26.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.26.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.26.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.26.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.26.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.26.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.26.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.26.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.26.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.26.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.26.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.26.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.26.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.26.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.26.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.26.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.27. Sweden
      • 8.3.27.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.27.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.27.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.27.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.27.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.27.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.27.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.27.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.27.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.27.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.27.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.27.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.27.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.27.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.27.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.27.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.28. Switzerland
      • 8.3.28.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.28.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.28.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.28.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.28.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.28.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.28.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.28.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.28.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.28.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.28.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.28.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.28.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.28.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.28.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.28.4. Market size, by technology, 2014 - 2025 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Market size, by country, 2014 - 2025 (USD Million)
    • 8.4.2. Market size, by product, 2014 - 2025 (USD Million)
      • 8.4.2.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.4.2.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
      • 8.4.2.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.4.2.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
        • 8.4.2.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
        • 8.4.2.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
    • 8.4.3. Market size, by application, 2014 - 2025 (USD Million)
      • 8.4.3.1. Market size, by hematology, 2014 - 2025 (USD Million)
      • 8.4.3.2. Market size, by oncology, 2014 - 2025 (USD Million)
        • 8.4.3.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
      • 8.4.3.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
        • 8.4.3.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
        • 8.4.3.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
    • 8.4.4. Market size, by manufacturer, 2014 - 2025 (USD Million)
    • 8.4.5. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.4.6. China
      • 8.4.6.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.4.6.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.4.6.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.4.6.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.4.6.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.4.6.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.4.6.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.4.6.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.4.6.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.4.6.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.4.6.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.4.6.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.4.6.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.4.6.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.4.6.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.4.6.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.4.7. Japan
      • 8.4.7.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.4.7.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.4.7.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.4.7.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.4.7.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
      • 8.4.7.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.4.7.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.4.7.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.4.7.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.4.7.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.4.7.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.4.7.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.4.7.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.4.7.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.4.8. India
      • 8.4.8.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.4.8.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.4.8.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.4.8.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.4.8.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.4.8.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.4.8.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.4.8.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.4.8.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.4.8.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.4.8.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.4.8.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.4.8.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.4.8.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.4.8.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.4.8.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.4.9. South Korea
      • 8.4.9.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.4.9.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.4.9.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.4.9.1.2.1. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
      • 8.4.9.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.4.9.2.1. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.4.9.2.1.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.4.9.2.2. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.4.9.2.2.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.4.9.2.2.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.4.9.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.4.9.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.4.10. Australia
      • 8.4.10.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.4.10.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.4.10.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.4.10.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.4.10.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.4.10.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.4.10.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.4.10.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.4.10.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.4.10.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.4.10.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.4.10.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.4.10.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.4.10.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.4.10.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.4.11. New Zealand
      • 8.4.11.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.4.11.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.4.11.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.4.11.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
      • 8.4.11.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.4.11.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.4.11.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.4.11.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
      • 8.4.11.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.4.11.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.4.12. Singapore
      • 8.4.12.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.4.12.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.4.12.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.4.12.1.2.1. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
      • 8.4.12.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.4.12.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.4.12.2.2. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.4.12.2.2.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.4.12.2.2.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.4.12.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.4.12.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.4.13. Malaysia
      • 8.4.13.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.4.13.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.4.13.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.4.13.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
      • 8.4.13.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.4.13.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.4.13.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.4.13.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
      • 8.4.13.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.4.13.4. Market size, by technology, 2014 - 2025 (USD Million)

Chapter 9. Company Profiles

  • 9.1. 3SBio
    • 9.1.1. Business overview
    • 9.1.2. Financial data
    • 9.1.3. Product landscape
    • 9.1.4. Strategic outlook
    • 9.1.5. SWOT analysis
  • 9.2. Amgen
    • 9.2.1. Business overview
    • 9.2.2. Financial data
    • 9.2.3. Product landscape
    • 9.2.4. Strategic outlook
    • 9.2.5. SWOT analysis
  • 9.3. Biocon
    • 9.3.1. Business overview
    • 9.3.2. Financial data
    • 9.3.3. Product landscape
    • 9.3.4. Strategic outlook
    • 9.3.5. SWOT analysis
  • 9.4. Biogen
    • 9.4.1. Business overview
    • 9.4.2. Financial data
    • 9.4.3. Product landscape
    • 9.4.4. Strategic outlook
    • 9.4.5. SWOT analysis
  • 9.5. Boehringer Ingelheim
    • 9.5.1. Business overview
    • 9.5.2. Financial data
    • 9.5.3. Product landscape
    • 9.5.4. Strategic outlook
    • 9.5.5. SWOT analysis
  • 9.6. Celltrion
    • 9.6.1. Business overview
    • 9.6.2. Financial data
    • 9.6.3. Product landscape
    • 9.6.4. Strategic outlook
    • 9.6.5. SWOT analysis
  • 9.7. Coherus BioSciences
    • 9.7.1. Business overview
    • 9.7.2. Financial data
    • 9.7.3. Product landscape
    • 9.7.4. Strategic outlook
    • 9.7.5. SWOT analysis
  • 9.8. Dr. Reddy's Laboratories
    • 9.8.1. Business overview
    • 9.8.2. Financial data
    • 9.8.3. Product landscape
    • 9.8.4. Strategic outlook
    • 9.8.5. SWOT analysis
  • 9.9. Elli Lilly and Company
    • 9.9.1. Business overview
    • 9.9.2. Financial data
    • 9.9.3. Product landscape
    • 9.9.4. Strategic outlook
    • 9.9.5. SWOT analysis
  • 9.10. Intas Biopharmaceuticals
    • 9.10.1. Business overview
    • 9.10.2. Financial data
    • 9.10.3. Product landscape
    • 9.10.4. Strategic outlook
    • 9.10.5. SWOT analysis
  • 9.11. Lupin
    • 9.11.1. Business overview
    • 9.11.2. Financial data
    • 9.11.3. Product landscape
    • 9.11.4. Strategic outlook
    • 9.11.5. SWOT analysis
  • 9.12. Merck
    • 9.12.1. Business overview
    • 9.12.2. Financial data
    • 9.12.3. Product landscape
    • 9.12.4. Strategic outlook
    • 9.12.5. SWOT analysis
  • 9.13. Novartis (Sandoz)
    • 9.13.1. Business overview
    • 9.13.2. Financial data
    • 9.13.3. Product landscape
    • 9.13.4. Strategic outlook
    • 9.13.5. SWOT analysis
  • 9.14. Ratiopharm
    • 9.14.1. Business overview
    • 9.14.2. Financial data
    • 9.14.3. Product landscape
    • 9.14.4. Strategic outlook
    • 9.14.5. SWOT analysis
  • 9.15. Samsung Bioepis
    • 9.15.1. Business overview
    • 9.15.2. Financial data
    • 9.15.3. Product landscape
    • 9.15.4. Strategic outlook
    • 9.15.5. SWOT analysis
  • 9.16. Sanofi
    • 9.16.1. Business overview
    • 9.16.2. Financial data
    • 9.16.3. Product landscape
    • 9.16.4. Strategic outlook
    • 9.16.5. SWOT analysis
  • 9.17. STADA Arzneimittel
    • 9.17.1. Business overview
    • 9.17.2. Financial data
    • 9.17.3. Product landscape
    • 9.17.4. Strategic outlook
    • 9.17.5. SWOT analysis
  • 9.18. Teva Pharmaceutical
    • 9.18.1. Business overview
    • 9.18.2. Financial data
    • 9.18.3. Product landscape
    • 9.18.4. Strategic outlook
    • 9.18.5. SWOT analysis
  • 9.19. Wockhardt
    • 9.19.1. Business overview
    • 9.19.2. Financial data
    • 9.19.3. Product landscape
    • 9.19.4. Strategic outlook
    • 9.19.5. SWOT analysis
  • 9.20. Zydus Cadila
    • 9.20.1. Business overview
    • 9.20.2. Financial data
    • 9.20.3. Product landscape
    • 9.20.4. Strategic outlook
    • 9.20.5. SWOT analysis

Data Tables

  • TABLE 1: Biosimilars industry 360 degree synopsis, 2014 - 2025
  • TABLE 2: Global biosimilars market, 2014 - 2018 (USD Million)
  • TABLE 3: Global biosimilars market, 2019 - 2025 (USD Million)
  • TABLE 4: Global biosimilars market, by product, 2014 - 2018 (USD Million)
  • TABLE 5: Global biosimilars market, by product, 2019 - 2025 (USD Million)
  • TABLE 6: Global biosimilars market, by application, 2014 - 2018 (USD Million)
  • TABLE 7: Global biosimilars market, by application, 2019 - 2025 (USD Million)
  • TABLE 8: Global biosimilars market, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 9: Global biosimilars market, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 10: Global biosimilars market, by technology, 2014 - 2018 (USD Million)
  • TABLE 11: Global biosimilars market, by technology, 2019 - 2025 (USD Million)
  • TABLE 12: Global biosimilars market, by region, 2014 - 2018 (USD Million)
  • TABLE 13: Global biosimilars market, by region, 2019 - 2025 (USD Million)
  • TABLE 14: Industry impact forces
  • TABLE 15: Amgen biosimilar product pipeline analysis
  • TABLE 16: Biocon biosimilar product pipeline analysis
  • TABLE 17: Boehringer Ingelheim biosimilar product pipeline analysis
  • TABLE 18: Celltrion biosimilar product pipeline analysis
  • TABLE 19: Coherus BioSciences biosimilar product pipeline analysis
  • TABLE 20: Dr. Reddy's Laboratories biosimilar product pipeline analysis
  • TABLE 21: Lupin biosimilar product pipeline analysis
  • TABLE 22: Merck biosimilar product pipeline analysis
  • TABLE 23: Novartis (Sandoz) biosimilar product pipeline analysis
  • TABLE 24: Pfizer biosimilar product pipeline analysis
  • TABLE 25: Samsung Bioepis biosimilar product pipeline analysis
  • TABLE 26: Teva Pharmaceutical biosimilar product pipeline analysis
  • TABLE 27: Zydus Cadila biosimilar product pipeline analysis
  • TABLE 28: U.S. biosimilar approval scenario
  • TABLE 29: Canada biosimilar approval scenario
  • TABLE 30: Europe biosimilar approval scenario
  • TABLE 31: Japan biosimilar approval scenario
  • TABLE 32: India biosimilar approval scenario
  • TABLE 33: South Korea biosimilar approval scenario
  • TABLE 34: Australia biosimilar approval scenario
  • TABLE 35: New Zealand biosimilar approval scenario
  • TABLE 36: Singapore biosimilar approval scenario
  • TABLE 37: Malaysia biosimilar approval scenario
  • TABLE 38: Patent expiry scenario
  • TABLE 39: Recombinant non-glycosylated proteins market size, by region, 2014 - 2018 (USD Million)
  • TABLE 40: Recombinant non-glycosylated proteins market size, by region, 2019 - 2025 (USD Million)
  • TABLE 41: Human growth hormone market size, by region, 2014 - 2018 (USD Million)
  • TABLE 42: Human growth hormone market size, by region, 2019 - 2025 (USD Million)
  • TABLE 43: Granulocyte colony-stimulating factor (Filgrastim) market size, by region, 2014 - 2018 (USD Million)
  • TABLE 44: Granulocyte colony-stimulating factor (Filgrastim) market size, by region, 2019 - 2025 (USD Million)
  • TABLE 45: Insulin market size, by region, 2014 - 2018 (USD Million)
  • TABLE 46: Insulin market size, by region, 2019 - 2025 (USD Million)
  • TABLE 47: Interferon market size, by region, 2014 - 2018 (USD Million)
  • TABLE 48: Interferon market size, by region, 2019 - 2025 (USD Million)
  • TABLE 49: Alfa market size, by region, 2014 - 2018 (USD Million)
  • TABLE 50: Alfa market size, by region, 2019 - 2025 (USD Million)
  • TABLE 51: Beta market size, by region, 2014 - 2018 (USD Million)
  • TABLE 52: Beta market size, by region, 2019 - 2025 (USD Million)
  • TABLE 53: Recombinant glycosylated proteins market size, by region, 2014 - 2018 (USD Million)
  • TABLE 54: Recombinant glycosylated proteins market size, by region, 2019 - 2025 (USD Million)
  • TABLE 55: Erythropoietin market size, by region, 2014 - 2018 (USD Million)
  • TABLE 56: Erythropoietin market size, by region, 2019 - 2025 (USD Million)
  • TABLE 57: Alfa market size, by region, 2014 - 2018 (USD Million)
  • TABLE 58: Alfa market size, by region, 2019 - 2025 (USD Million)
  • TABLE 59: Zeta market size, by region, 2014 - 2018 (USD Million)
  • TABLE 60: Zeta market size, by region, 2019 - 2025 (USD Million)
  • TABLE 61: Monoclonal antibodies market size, by region, 2014 - 2018 (USD Million)
  • TABLE 62: Monoclonal antibodies market size, by region, 2019 - 2025 (USD Million)
  • TABLE 63: Infliximab market size, by region, 2014 - 2018 (USD Million)
  • TABLE 64: Infliximab market size, by region, 2019 - 2025 (USD Million)
  • TABLE 65: Rituximab market size, by region, 2014 - 2018 (USD Million)
  • TABLE 66: Rituximab market size, by region, 2019 - 2025 (USD Million)
  • TABLE 67: Adalimumab market size, by region, 2014 - 2018 (USD Million)
  • TABLE 68: Adalimumab market size, by region, 2019 - 2025 (USD Million)
  • TABLE 69: Trastuzumab market size, by region, 2014 - 2018 (USD Million)
  • TABLE 70: Trastuzumab market size, by region, 2019 - 2025 (USD Million)
  • TABLE 71: Bevacizumab market size, by region, 2014 - 2018 (USD Million)
  • TABLE 72: Bevacizumab market size, by region, 2019 - 2025 (USD Million)
  • TABLE 73: Etanercept market size, by region, 2014 - 2018 (USD Million)
  • TABLE 74: Etanercept market size, by region, 2019 - 2025 (USD Million)
  • TABLE 75: Follitropin market size, by region, 2014 - 2018 (USD Million)
  • TABLE 76: Follitropin market size, by region, 2019 - 2025 (USD Million)
  • TABLE 77: Alfa market size, by region, 2014 - 2018 (USD Million)
  • TABLE 78: Alfa market size, by region, 2019 - 2025 (USD Million)
  • TABLE 79: Beta market size, by region, 2014 - 2018 (USD Million)
  • TABLE 80: Beta market size, by region, 2019 - 2025 (USD Million)
  • TABLE 81: Low molecular weight heparin market size, by region, 2014 - 2018 (USD Million)
  • TABLE 82: Low molecular weight heparin market size, by region, 2019 - 2025 (USD Million)
  • TABLE 83: Hematology market size, by region, 2014 - 2018 (USD Million)
  • TABLE 84: Hematology market size, by region, 2019 - 2025 (USD Million)
  • TABLE 85: Neutropenia market size, by region, 2014 - 2018 (USD Million)
  • TABLE 86: Neutropenia market size, by region, 2019 - 2025 (USD Million)
  • TABLE 87: Anemia market size, by region, 2014 - 2018 (USD Million)
  • TABLE 88: Anemia market size, by region, 2019 - 2025 (USD Million)
  • TABLE 89: Others market size, by region, 2014 - 2018 (USD Million)
  • TABLE 90: Others market size, by region, 2019 - 2025 (USD Million)
  • TABLE 91: Oncology market size, by region, 2014 - 2018 (USD Million)
  • TABLE 92: Oncology market size, by region, 2019 - 2025 (USD Million)
  • TABLE 93: Lung cancer market size, by region, 2014 - 2018 (USD Million)
  • TABLE 94: Lung cancer market size, by region, 2019 - 2025 (USD Million)
  • TABLE 95: Brain cancer market size, by region, 2014 - 2018 (USD Million)
  • TABLE 96: Brain cancer market size, by region, 2019 - 2025 (USD Million)
  • TABLE 97: Breast cancer market size, by region, 2014 - 2018 (USD Million)
  • TABLE 98: Breast cancer market size, by region, 2019 - 2025 (USD Million)
  • TABLE 99: Cervical cancer market size, by region, 2014 - 2018 (USD Million)
  • TABLE 100: Cervical cancer market size, by region, 2019 - 2025 (USD Million)
  • TABLE 101: Colorectal cancer market size, by region, 2014 - 2018 (USD Million)
  • TABLE 102: Colorectal cancer market size, by region, 2019 - 2025 (USD Million)
  • TABLE 103: Leukemia market size, by region, 2014 - 2018 (USD Million)
  • TABLE 104: Leukemia market size, by region, 2019 - 2025 (USD Million)
  • TABLE 105: Non-Hodgkin lymphoma (NHL) market size, by region, 2014 - 2018 (USD Million)
  • TABLE 106: Non-Hodgkin lymphoma (NHL) market size, by region, 2019 - 2025 (USD Million)
  • TABLE 107: Chronic lymphocytic leukemia (CLL) market size, by region, 2014 - 2018 (USD Million)
  • TABLE 108: Chronic lymphocytic leukemia (CLL) market size, by region, 2019 - 2025 (USD Million)
  • TABLE 109: Others market size, by region, 2014 - 2018 (USD Million)
  • TABLE 110: Others market size, by region, 2019 - 2025 (USD Million)
  • TABLE 111: Others market size, by region, 2014 - 2018 (USD Million)
  • TABLE 112: Others market size, by region, 2019 - 2025 (USD Million)
  • TABLE 113: Autoimmune disease market size, by region, 2014 - 2018 (USD Million)
  • TABLE 114: Autoimmune disease market size, by region, 2019 - 2025 (USD Million)
  • TABLE 115: Arthritis market size, by region, 2014 - 2018 (USD Million)
  • TABLE 116: Arthritis market size, by region, 2019 - 2025 (USD Million)
  • TABLE 117: Rheumatoid arthritis market size, by region, 2014 - 2018 (USD Million)
  • TABLE 118: Rheumatoid arthritis market size, by region, 2019 - 2025 (USD Million)
  • TABLE 119: Psoriatic arthritis market size, by region, 2014 - 2018 (USD Million)
  • TABLE 120: Psoriatic arthritis market size, by region, 2019 - 2025 (USD Million)
  • TABLE 121: Juvenile arthritis market size, by region, 2014 - 2018 (USD Million)
  • TABLE 122: Juvenile arthritis market size, by region, 2019 - 2025 (USD Million)
  • TABLE 123: Ankylosing spondylitis market size, by region, 2014 - 2018 (USD Million)
  • TABLE 124: Ankylosing spondylitis market size, by region, 2019 - 2025 (USD Million)
  • TABLE 125: Others market size, by region, 2014 - 2018 (USD Million)
  • TABLE 126: Others market size, by region, 2019 - 2025 (USD Million)
  • TABLE 127: Inflammatory bowel disease market size, by region, 2014 - 2018 (USD Million)
  • TABLE 128: Inflammatory bowel disease market size, by region, 2019 - 2025 (USD Million)
  • TABLE 129: Ulcerative colitis market size, by region, 2014 - 2018 (USD Million)
  • TABLE 130: Ulcerative colitis market size, by region, 2019 - 2025 (USD Million)
  • TABLE 131: Crohn's disease market size, by region, 2014 - 2018 (USD Million)
  • TABLE 132: Crohn's disease market size, by region, 2019 - 2025 (USD Million)
  • TABLE 133: Others market size, by region, 2014 - 2018 (USD Million)
  • TABLE 134: Others market size, by region, 2019 - 2025 (USD Million)
  • TABLE 135: Growth hormone deficiency market size, by region, 2014 - 2018 (USD Million)
  • TABLE 136: Growth hormone deficiency market size, by region, 2019 - 2025 (USD Million)
  • TABLE 137: Diabetes market size, by region, 2014 - 2018 (USD Million)
  • TABLE 138: Diabetes market size, by region, 2019 - 2025 (USD Million)
  • TABLE 139: Others market size, by region, 2014 - 2018 (USD Million)
  • TABLE 140: Others market size, by region, 2019 - 2025 (USD Million)
  • TABLE 141: Contract research and manufacturing services market size, by region, 2014 - 2018 (USD Million)
  • TABLE 142: Contract research and manufacturing services market size, by region, 2019 - 2025 (USD Million)
  • TABLE 143: In-house market size, by region, 2014 - 2018 (USD Million)
  • TABLE 144: In-house market size, by region, 2019 - 2025 (USD Million)
  • TABLE 145: Recombinant DNA technology (rDNA technology) market size, by region, 2014 - 2018 (USD Million)
  • TABLE 146: Recombinant DNA technology (rDNA technology) market size, by region, 2019 - 2025 (USD Million)
  • TABLE 147: Monoclonal antibodies (MAb) technology market size, by region, 2014 - 2018 (USD Million)
  • TABLE 148: Monoclonal antibodies (MAb) technology market size, by region, 2019 - 2025 (USD Million)
  • TABLE 149: North America biosimilars market size, by country, 2014 - 2018 (USD Million)
  • TABLE 150: North America biosimilars market size, by country, 2019 - 2025 (USD Million)
  • TABLE 151: North America biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 152: North America biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 153: North America biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 154: North America biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 155: North America biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 156: North America biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 157: North America biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 158: North America biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 159: North America biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 160: North America biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 161: North America biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 162: North America biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 163: North America biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 164: North America biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 165: North America biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 166: North America biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 167: North America biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 168: North America biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 169: North America biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 170: North America biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 171: North America biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 172: North America biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 173: North America biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 174: North America biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 175: North America biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 176: North America biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 177: U.S. biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 178: U.S. biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 179: U.S. biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 180: U.S. biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 181: U.S. biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 182: U.S. biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 183: U.S. biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 184: U.S. biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 185: U.S. biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 186: U.S. biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 187: U.S. biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 188: U.S. biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 189: U.S. biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 190: U.S. biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 191: U.S. biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 192: U.S. biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 193: U.S. biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 194: U.S. biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 195: U.S. biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 196: U.S. biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 197: U.S. biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 198: U.S. biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 199: U.S. biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 200: U.S. biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 201: U.S. biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 202: U.S. biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 203: Canada biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 204: Canada biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 205: Canada biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 206: Canada biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 207: Canada biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 208: Canada biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 209: Canada biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 210: Canada biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 211: Canada biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 212: Canada biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 213: Canada biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 214: Canada biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 215: Canada biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 216: Canada biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 217: Canada biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 218: Canada biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 219: Canada biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 220: Canada biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 221: Canada biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 222: Canada biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 223: Canada biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 224: Canada biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 225: Europe biosimilars market size, by country, 2014 - 2018 (USD Million)
  • TABLE 226: Europe biosimilars market size, by country, 2019 - 2025 (USD Million)
  • TABLE 227: Europe biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 228: Europe biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 229: Europe biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 230: Europe biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 231: Europe biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 232: Europe biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 233: Europe biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 234: Europe biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 235: Europe biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 236: Europe biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 237: Europe biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 238: Europe biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 239: Europe biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 240: Europe biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 241: Europe biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 242: Europe biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 243: Europe biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 244: Europe biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 245: Europe biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 246: Europe biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 247: Europe biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 248: Europe biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 249: Europe biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 250: Europe biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 251: Europe biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 252: Europe biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 253: Europe biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 254: Europe biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 255: Europe biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 256: Europe biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 257: Europe biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 258: Europe biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 259: Germany biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 260: Germany biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 261: Germany biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 262: Germany biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 263: Germany biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 264: Germany biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 265: Germany biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 266: Germany biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 267: Germany biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 268: Germany biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 269: Germany biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 270: Germany biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 271: Germany biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 272: Germany biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 273: Germany biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 274: Germany biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 275: Germany biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 276: Germany biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 277: Germany biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 278: Germany biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 279: Germany biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 280: Germany biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 281: Germany biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 282: Germany biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 283: Germany biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 284: Germany biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 285: Germany biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 286: Germany biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 287: Germany biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 288: Germany biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 289: Germany biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 290: Germany biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 291: UK biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 292: UK biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 293: UK biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 294: UK biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 295: UK biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 296: UK biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 297: UK biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 298: UK biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 299: UK biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 300: UK biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 301: UK biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 302: UK biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 303: UK biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 304: UK biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 305: UK biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 306: UK biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 307: UK biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 308: UK biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 309: UK biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 310: UK biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 311: UK biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 312: UK biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 313: UK biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 314: UK biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 315: UK biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 316: UK biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 317: UK biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 318: UK biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 319: UK biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 320: UK biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 321: UK biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 322: UK biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 323: France biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 324: France biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 325: France biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 326: France biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 327: France biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 328: France biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 329: France biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 330: France biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 331: France biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 332: France biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 333: France biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 334: France biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 335: France biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 336: France biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 337: France biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 338: France biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 339: France biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 340: France biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 341: France biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 342: France biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 343: France biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 344: France biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 345: France biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 346: France biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 347: France biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 348: France biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 349: France biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 350: France biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 351: France biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 352: France biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 353: France biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 354: France biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 355: Spain biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 356: Spain biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 357: Spain biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 358: Spain biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 359: Spain biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 360: Spain biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 361: Spain biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 362: Spain biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 363: Spain biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 364: Spain biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 365: Spain biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 366: Spain biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 367: Spain biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 368: Spain biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 369: Spain biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 370: Spain biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 371: Spain biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 372: Spain biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 373: Spain biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 374: Spain biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 375: Spain biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 376: Spain biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 377: Spain biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 378: Spain biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 379: Spain biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 380: Spain biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 381: Spain biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 382: Spain biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 383: Spain biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 384: Spain biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 385: Spain biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 386: Spain biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 387: Italy biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 388: Italy biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 389: Italy biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 390: Italy biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 391: Italy biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 392: Italy biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 393: Italy biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 394: Italy biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 395: Italy biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 396: Italy biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 397: Italy biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 398: Italy biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 399: Italy biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 400: Italy biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 401: Italy biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 402: Italy biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 403: Italy biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 404: Italy biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 405: Italy biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 406: Italy biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 407: Italy biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 408: Italy biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 409: Italy biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 410: Italy biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 411: Italy biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 412: Italy biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 413: Italy biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 414: Italy biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 415: Germany biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 416: Italy biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 417: Italy biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 418: Italy biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 419: Russia biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 420: Russia biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 421: Russia biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 422: Russia biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 423: Russia biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 424: Russia biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 425: Russia biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 426: Russia biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 427: Russia biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 428: Russia biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 429: Russia biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 430: Russia biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 431: Russia biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 432: Russia biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 433: Russia biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 434: Russia biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 435: Russia biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 436: Russia biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 437: Russia biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 438: Russia biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 439: Russia biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 440: Russia biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 441: Russia biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 442: Russia biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 443: Russia biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 444: Russia biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 445: Russia biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 446: Russia biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 447: Russia biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 448: Russia biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 449: Russia biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 450: Russia biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 451: Turkey biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 452: Turkey biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 453: Turkey biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 454: Turkey biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 455: Turkey biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 456: Turkey biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 457: Turkey biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 458: Turkey biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 459: Turkey biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 460: Turkey biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 461: Turkey biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 462: Turkey biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 463: Turkey biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 464: Turkey biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 465: Turkey biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 466: Turkey biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 467: Turkey biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 468: Turkey biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 469: Turkey biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 470: Turkey biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 471: Turkey biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 472: Turkey biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 473: Turkey biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 474: Turkey biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 475: Turkey biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 476: Turkey biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 477: Turkey biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 478: Turkey biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 479: Turkey biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 480: Germany biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 481: Turkey biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 482: Turkey biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 483: Austria biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 484: Austria biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 485: Austria biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 486: Austria biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 487: Austria biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 488: Austria biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 489: Austria biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 490: Austria biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 491: Austria biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 492: Austria biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 493: Austria biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 494: Austria biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 495: Austria biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 496: Austria biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 497: Austria biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 498: Austria biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 499: Austria biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 500: Austria biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 501: Austria biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 502: Austria biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 503: Austria biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 504: Austria biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 505: Austria biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 506: Austria biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 507: Austria biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 508: Austria biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 509: Austria biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 510: Austria biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 511: Austria biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 512: Austria biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 513: Austria biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 514: Austria biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 515: Belgium biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 516: Belgium biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 517: Belgium biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 518: Belgium biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 519: Belgium biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 520: Belgium biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 521: Belgium biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 522: Belgium biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 523: Belgium biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 524: Belgium biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 525: Belgium biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 526: Belgium biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 527: Belgium biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 528: Belgium biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 529: Belgium biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 530: Belgium biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 531: Belgium biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 532: Belgium biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 533: Belgium biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 534: Belgium biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 535: Belgium biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 536: Belgium biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 537: Belgium biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 538: Belgium biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 539: Belgium biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 540: Belgium biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 541: Belgium biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 542: Belgium biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 543: Belgium biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 544: Belgium biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 545: Belgium biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 546: Belgium biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 547: Bulgaria biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 548: Bulgaria biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 549: Bulgaria biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 550: Bulgaria biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 551: Bulgaria biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 552: Bulgaria biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 553: Bulgaria biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 554: Bulgaria biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 555: Bulgaria biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 556: Bulgaria biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 557: Bulgaria biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 558: Bulgaria biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 559: Bulgaria biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 560: Bulgaria biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 561: Bulgaria biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 562: Bulgaria biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 563: Bulgaria biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 564: Bulgaria biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 565: Bulgaria biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 566: Bulgaria biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 567: Bulgaria biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 568: Bulgaria biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 569: Bulgaria biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 570: Bulgaria biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 571: Bulgaria biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 572: Bulgaria biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 573: Bulgaria biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 574: Bulgaria biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 575: Bulgaria biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 576: Bulgaria biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 577: Bulgaria biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 578: Bulgaria biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 579: Czech Republic biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 580: Czech Republic biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 581: Czech Republic biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 582: Czech Republic biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 583: Czech Republic biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 584: Czech Republic biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 585: Czech Republic biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 586: Czech Republic biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 587: Czech Republic biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 588: Czech Republic biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 589: Czech Republic biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 590: Czech Republic biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 591: Czech Republic biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 592: Czech Republic biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 593: Czech Republic biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 594: Czech Republic biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 595: Czech Republic biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 596: Czech Republic biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 597: Czech Republic biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 598: Czech Republic biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 599: Czech Republic biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 600: Czech Republic biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 601: Czech Republic biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 602: Czech Republic biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 603: Czech Republic biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 604: Czech Republic biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 605: Czech Republic biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 606: Czech Republic biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 607: Czech Republic biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 608: Czech Republic biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 609: Czech Republic biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 610: Czech Republic biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 611: Denmark biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 612: Denmark biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 613: Denmark biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 614: Denmark biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 615: Denmark biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 616: Denmark biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 617: Denmark biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 618: Denmark biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 619: Denmark biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 620: Denmark biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 621: Denmark biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 622: Denmark biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 623: Denmark biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 624: Denmark biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 625: Denmark biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 626: Denmark biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 627: Denmark biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 628: Denmark biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 629: Denmark biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 630: Denmark biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 631: Denmark biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 632: Denmark biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 633: Denmark biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 634: Denmark biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 635: Denmark biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 636: Denmark biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 637: Denmark biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 638: Denmark biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 639: Denmark biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 640: Denmark biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 641: Denmark biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 642: Denmark biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 643: Finland biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 644: Finland biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 645: Finland biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 646: Finland biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 647: Finland biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 648: Finland biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 649: Finland biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 650: Finland biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 651: Finland biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 652: Finland biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 653: Finland biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 654: Finland biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 655: Finland biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 656: Finland biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 657: Finland biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 658: Finland biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 659: Finland biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 660: Finland biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 661: Finland biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 662: Finland biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 663: Finland biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 664: Finland biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 665: Finland biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 666: Finland biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 667: Finland biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 668: Finland biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 669: Finland biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 670: Finland biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 671: Finland biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 672: Finland biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 673: Finland biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 674: Finland biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 675: Greece biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 676: Greece biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 677: Greece biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 678: Greece biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 679: Greece biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 680: Greece biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 681: Greece biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 682: Greece biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 683: Greece biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 684: Greece biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 685: Greece biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 686: Greece biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 687: Greece biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 688: Greece biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 689: Greece biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 690: Greece biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 691: Greece biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 692: Greece biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 693: Greece biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 694: Greece biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 695: Greece biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 696: Greece biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 697: Greece biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 698: Greece biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 699: Greece biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 700: Greece biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 701: Greece biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 702: Greece biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 703: Greece biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 704: Greece biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 705: Greece biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 706: Greece biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 707: Hungary biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 708: Hungary biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 709: Hungary biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 710: Hungary biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 711: Hungary biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 712: Hungary biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 713: Hungary biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 714: Hungary biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 715: Hungary biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 716: Hungary biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 717: Hungary biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 718: Hungary biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 719: Hungary biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 720: Hungary biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 721: Hungary biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 722: Hungary biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 723: Hungary biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 724: Hungary biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 725: Hungary biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 726: Hungary biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 727: Hungary biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 728: Hungary biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 729: Hungary biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 730: Hungary biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 731: Hungary biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 732: Hungary biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 733: Hungary biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 734: Hungary biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 735: Hungary biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 736: Hungary biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 737: Hungary biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 738: Hungary biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 739: Ireland biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 740: Ireland biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 741: Ireland biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 742: Ireland biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 743: Ireland biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 744: Ireland biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 745: Ireland biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 746: Ireland biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 747: Ireland biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 748: Ireland biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 749: Ireland biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 750: Ireland biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 751: Ireland biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 752: Ireland biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 753: Ireland biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 754: Ireland biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 755: Ireland biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 756: Ireland biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 757: Ireland biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 758: Ireland biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 759: Ireland biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 760: Ireland biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 761: Ireland biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 762: Ireland biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 763: Ireland biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 764: Ireland biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 765: Ireland biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 766: Ireland biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 767: Ireland biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 768: Ireland biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 769: Ireland biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 770: Ireland biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 771: Netherlands biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 772: Netherlands biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 773: Netherlands biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 774: Netherlands biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 775: Netherlands biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 776: Netherlands biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 777: Netherlands biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 778: Netherlands biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 779: Netherlands biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 780: Netherlands biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 781: Netherlands biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 782: Netherlands biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 783: Netherlands biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 784: Netherlands biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 785: Netherlands biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 786: Netherlands biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 787: Netherlands biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 788: Netherlands biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 789: Netherlands biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 790: Netherlands biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 791: Netherlands biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 792: Netherlands biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 793: Netherlands biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 794: Netherlands biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 795: Netherlands biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 796: Netherlands biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 797: Netherlands biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 798: Netherlands biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 799: Netherlands biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 800: Netherlands biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 801: Netherlands biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 802: Netherlands biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 803: Norway biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 804: Norway biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 805: Norway biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 806: Norway biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 807: Norway biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 808: Norway biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 809: Norway biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 810: Norway biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 811: Norway biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 812: Norway biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 813: Norway biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 814: Norway biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 815: Norway biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 816: Norway biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 817: Norway biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 818: Norway biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 819: Norway biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 820: Norway biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 821: Norway biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 822: Norway biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 823: Norway biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 824: Norway biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 825: Norway biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 826: Norway biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 827: Norway biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 828: Norway biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 829: Norway biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 830: Norway biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 831: Norway biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 832: Norway biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 833: Norway biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 834: Norway biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 835: Romania biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 836: Romania biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 837: Romania biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 838: Romania biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 839: Romania biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 840: Romania biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 841: Romania biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 842: Romania biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 843: Romania biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 844: Romania biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 845: Romania biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 846: Romania biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 847: Romania biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 848: Romania biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 849: Romania biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 850: Romania biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 851: Romania biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 852: Romania biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 853: Romania biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 854: Romania biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 855: Romania biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 856: Romania biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 857: Romania biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 858: Romania biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 859: Romania biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 860: Romania biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 861: Romania biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 862: Romania biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 863: Romania biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 864: Romania biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 865: Romania biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 866: Romania biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 867: Slovakia biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 868: Slovakia biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 869: Slovakia biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 870: Slovakia biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 871: Slovakia biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 872: Slovakia biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 873: Slovakia biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 874: Slovakia biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 875: Slovakia biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 876: Slovakia biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 877: Slovakia biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 878: Slovakia biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 879: Slovakia biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 880: Slovakia biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 881: Slovakia biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 882: Slovakia biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 883: Slovakia biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 884: Slovakia biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 885: Slovakia biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 886: Slovakia biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 887: Slovakia biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 888: Slovakia biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 889: Slovakia biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 890: Slovakia biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 891: Slovakia biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 892: Slovakia biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 893: Slovakia biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 894: Slovakia biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 895: Slovakia biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 896: Slovakia biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 897: Slovakia biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 898: Slovakia biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 899: Slovenia biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 900: Slovenia biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 901: Slovenia biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 902: Slovenia biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 903: Slovenia biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 904: Slovenia biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 905: Slovenia biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 906: Slovenia biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 907: Slovenia biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 908: Slovenia biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 909: Slovenia biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 910: Slovenia biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 911: Slovenia biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 912: Slovenia biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 913: Slovenia biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 914: Slovenia biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 915: Slovenia biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 916: Slovenia biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 917: Slovenia biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 918: Slovenia biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 919: Slovenia biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 920: Slovenia biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 921: Slovenia biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 922: Slovenia biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 923: Slovenia biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 924: Slovenia biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 925: Slovenia biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 926: Slovenia biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 927: Slovenia biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 928: Slovenia biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 929: Slovenia biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 930: Slovenia biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 931: Sweden biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 932: Sweden biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 933: Sweden biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 934: Sweden biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 935: Sweden biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 936: Sweden biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 937: Sweden biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 938: Sweden biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 939: Sweden biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 940: Sweden biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 941: Sweden biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 942: Sweden biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 943: Sweden biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 944: Sweden biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 945: Sweden biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 946: Sweden biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 947: Sweden biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 948: Sweden biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 949: Sweden biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 950: Sweden biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 951: Sweden biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 952: Sweden biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 953: Sweden biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 954: Sweden biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 955: Sweden biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 956: Sweden biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 957: Sweden biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 958: Sweden biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 959: Sweden biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 960: Sweden biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 961: Sweden biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 962: Sweden biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 963: Switzerland biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 964: Switzerland biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 965: Switzerland biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 966: Switzerland biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 967: Switzerland biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 968: Switzerland biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 969: Switzerland biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 970: Switzerland biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 971: Switzerland biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 972: Switzerland biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 973: Switzerland biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 974: Switzerland biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 975: Switzerland biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 976: Switzerland biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 977: Switzerland biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 978: Switzerland biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 979: Switzerland biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 980: Switzerland biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 981: Switzerland biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 982: Switzerland biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 983: Switzerland biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 984: Switzerland biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 985: Switzerland biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 986: Switzerland biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 987: Switzerland biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 988: Switzerland biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 989: Switzerland biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 990: Switzerland biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 991: Switzerland biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 992: Switzerland biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 993: Switzerland biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 994: Switzerland biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 995: Asia Pacific biosimilars market size, by country, 2014 - 2018 (USD Million)
  • TABLE 996: Asia Pacific biosimilars market size, by country, 2019 - 2025 (USD Million)
  • TABLE 997: Asia Pacific biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 998: Asia Pacific biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 999: Asia Pacific biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 1000: Asia Pacific biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 1001: Asia Pacific biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 1002: Asia Pacific biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 1003: Asia Pacific biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 1004: Asia Pacific biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 1005: Asia Pacific biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 1006: Asia Pacific biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 1007: Asia Pacific biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 1008: Asia Pacific biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 1009: Asia Pacific biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 1010: Asia Pacific biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 1011: Asia Pacific biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 1012: Asia Pacific biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 1013: Asia Pacific biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 1014: Asia Pacific biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 1015: Asia Pacific biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 1016: Asia Pacific biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 1017: Asia Pacific biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 1018: Asia Pacific biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 1019: Asia Pacific biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 1020: Asia Pacific biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 1021: Asia Pacific biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 1022: Asia Pacific biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 1023: Asia Pacific biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 1024: Asia Pacific biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 1025: Asia Pacific biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 1026: Asia Pacific biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 1027: Asia Pacific biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 1028: Asia Pacific biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 1029: China biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 1030: China biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 1031: China biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 1032: China biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 1033: China biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 1034: China biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 1035: China biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 1036: China biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 1037: China biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 1038: China biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 1039: China biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 1040: China biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 1041: China biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 1042: China biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 1043: China biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 1044: China biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 1045: China biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 1046: China biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 1047: China biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 1048: China biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 1049: China biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 1050: China biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 1051: China biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 1052: China biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 1053: China biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 1054: China biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 1055: China biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 1056: China biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 1057: China biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 1058: China biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 1059: China biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 1060: China biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 1061: Japan biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 1062: Japan biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 1063: Japan biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 1064: Japan biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 1065: Japan biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 1066: Japan biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 1067: Japan biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 1068: Japan biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 1069: Japan biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 1070: Japan biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 1071: Japan biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 1072: Japan biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 1073: Japan biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 1074: Japan biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 1075: Japan biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 1076: Japan biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 1077: Japan biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 1078: Japan biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 1079: Japan biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 1080: Japan biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 1081: Japan biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 1082: Japan biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 1083: Japan biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 1084: Japan biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 1085: Japan biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 1086: Japan biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 1087: Japan biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 1088: Japan biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 1089: India biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 1090: India biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 1091: India biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 1092: India biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 1093: India biosimilars market size, by interferon, 2014 - 2018 (USD Million)
  • TABLE 1094: India biosimilars market size, by interferon, 2019 - 2025 (USD Million)
  • TABLE 1095: India biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 1096: India biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 1097: India biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 1098: India biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 1099: India biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 1100: India biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 1101: India biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 1102: India biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 1103: India biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 1104: India biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 1105: India biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 1106: India biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 1107: India biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 1108: India biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 1109: India biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 1110: India biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 1111: India biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 1112: India biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 1113: India biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 1114: India biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 1115: India biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 1116: India biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 1117: India biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 1118: India biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 1119: India biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 1120: India biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 1121: South Korea biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 1122: South Korea biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 1123: South Korea biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 1124: South Korea biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 1125: South Korea biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 1126: South Korea biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 1127: South Korea biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 1128: South Korea biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 1129: South Korea biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 1130: South Korea biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 1131: South Korea biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 1132: South Korea biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 1133: South Korea biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 1134: South Korea biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 1135: South Korea biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 1136: South Korea biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 1137: South Korea biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 1138: South Korea biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 1139: South Korea biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 1140: South Korea biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 1141: South Korea biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 1142: South Korea biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 1143: South Korea biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 1144: South Korea biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 1145: Australia biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 1146: Australia biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 1147: Australia biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 1148: Australia biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 1149: Australia biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 1150: Australia biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 1151: Australia biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 1152: Australia biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 1153: Australia biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 1154: Australia biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 1155: Australia biosimilars market size, by follitropin, 2014 - 2018 (USD Million)
  • TABLE 1156: Australia biosimilars market size, by follitropin, 2019 - 2025 (USD Million)
  • TABLE 1157: Australia biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 1158: Australia biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 1159: Australia biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 1160: Australia biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 1161: Australia biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 1162: Australia biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 1163: Australia biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 1164: Australia biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 1165: Australia biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 1166: Australia biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 1167: Australia biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 1168: Australia biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 1169: Australia biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 1170: Australia biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 1171: Australia biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 1172: Australia biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 1173: Australia biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 1174: Australia biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 1175: New Zealand biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 1176: New Zealand biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 1177: New Zealand biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 1178: New Zealand biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 1179: New Zealand biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 1180: New Zealand biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 1181: New Zealand biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 1182: New Zealand biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 1183: New Zealand biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 1184: New Zealand biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 1185: New Zealand biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 1186: New Zealand biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 1187: New Zealand biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 1188: New Zealand biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 1189: New Zealand biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 1190: New Zealand biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 1191: New Zealand biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 1192: New Zealand biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 1193: New Zealand biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 1194: New Zealand biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 1195: Singapore biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 1196: Singapore biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 1197: Singapore biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 1198: Singapore biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 1199: Singapore biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 1200: Singapore biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 1201: Singapore biosimilars market size, by monoclonal antibodies, 2014 - 2018 (USD Million)
  • TABLE 1202: Singapore biosimilars market size, by monoclonal antibodies, 2019 - 2025 (USD Million)
  • TABLE 1203: Singapore biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 1204: Singapore biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 1205: Singapore biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 1206: Singapore biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 1207: Singapore biosimilars market size, by autoimmune disease, 2014 - 2018 (USD Million)
  • TABLE 1208: Singapore biosimilars market size, by autoimmune disease, 2019 - 2025 (USD Million)
  • TABLE 1209: Singapore biosimilars market size, by arthritis, 2014 - 2018 (USD Million)
  • TABLE 1210: Singapore biosimilars market size, by arthritis, 2019 - 2025 (USD Million)
  • TABLE 1211: Singapore biosimilars market size, by inflammatory bowel disease, 2014 - 2018 (USD Million)
  • TABLE 1212: Singapore biosimilars market size, by inflammatory bowel disease, 2019 - 2025 (USD Million)
  • TABLE 1213: Singapore biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 1214: Singapore biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 1215: Singapore biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 1216: Singapore biosimilars market size, by technology, 2019 - 2025 (USD Million)
  • TABLE 1217: Malaysia biosimilars market size, by product, 2014 - 2018 (USD Million)
  • TABLE 1218: Malaysia biosimilars market size, by product, 2019 - 2025 (USD Million)
  • TABLE 1219: Malaysia biosimilars market size, by recombinant non-glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 1220: Malaysia biosimilars market size, by recombinant non-glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 1221: Malaysia biosimilars market size, by recombinant glycosylated proteins, 2014 - 2018 (USD Million)
  • TABLE 1222: Malaysia biosimilars market size, by recombinant glycosylated proteins, 2019 - 2025 (USD Million)
  • TABLE 1223: Malaysia biosimilars market size, by erythropoietin, 2014 - 2018 (USD Million)
  • TABLE 1224: Malaysia biosimilars market size, by erythropoietin, 2019 - 2025 (USD Million)
  • TABLE 1225: Malaysia biosimilars market size, by application, 2014 - 2018 (USD Million)
  • TABLE 1226: Malaysia biosimilars market size, by application, 2019 - 2025 (USD Million)
  • TABLE 1227: Malaysia biosimilars market size, by hematology, 2014 - 2018 (USD Million)
  • TABLE 1228: Malaysia biosimilars market size, by hematology, 2019 - 2025 (USD Million)
  • TABLE 1229: Malaysia biosimilars market size, by oncology, 2014 - 2018 (USD Million)
  • TABLE 1230: Malaysia biosimilars market size, by oncology, 2019 - 2025 (USD Million)
  • TABLE 1231: Malaysia biosimilars market size, by leukemia, 2014 - 2018 (USD Million)
  • TABLE 1232: Malaysia biosimilars market size, by leukemia, 2019 - 2025 (USD Million)
  • TABLE 1233: Malaysia biosimilars market size, by manufacturer, 2014 - 2018 (USD Million)
  • TABLE 1234: Malaysia biosimilars market size, by manufacturer, 2019 - 2025 (USD Million)
  • TABLE 1235: Malaysia biosimilars market size, by technology, 2014 - 2018 (USD Million)
  • TABLE 1236: Malaysia biosimilars market size, by technology, 2019 - 2025 (USD Million)

Charts & Figures

  • FIG. 1: Industry segmentation
  • FIG. 2: Global biosimilars market, 2014 - 2025 (USD Million)
  • FIG. 3: Growth potential analysis, by product
  • FIG. 4: Growth potential analysis, by application
  • FIG. 5: Growth potential analysis, by manufacturer
  • FIG. 6: Growth potential analysis, by technology
  • FIG. 7: Porter's analysis
  • FIG. 8: Strategy dashboard
  • FIG. 9: PESTEL analysis
Back to Top